← All trials
NCT02444793
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 26, 2015
- Primary completion
- Aug 10, 2017
- Completion date
- Aug 10, 2017
- First posted
- —
- Last posted
- —
- Enrollment
- 70
- Arms / groups
- 1 / —
- Source
- AACT · pre-existing
Sponsors
- PfizerLead sponsor
- Georgetown UniversityOverall official - principal investigator
- University of California, San DiegoOverall official - principal investigator
- PfizerStudy director
- Kyowa Hakko KirinCollaborator
- University of RochesterOverall official - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.